<DOC>
	<DOC>NCT00683800</DOC>
	<brief_summary>The purpose of the study is to evaluate the efficacy and safety of Desvenlafaxine Succinate (DVS) Sustained Release (SR), in comparison to placebo for the treatment of Vasomotor Symptoms (VMS) in menopausal women.</brief_summary>
	<brief_title>Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Generally healthy, postmenopausal women who seek treatment for hot flushes Body Mass Index (BMI) less than or equal to 34 kg/m^2 Hypersensitivity to Venlafaxine Myocardial infarction an/or unstable angina within 6 months of screening History of seizure disorder</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Menopause</keyword>
	<keyword>Hot Flush</keyword>
	<keyword>Hot Flash</keyword>
	<keyword>Desvenlafaxine succinate Sustained Release</keyword>
</DOC>